Based on our data, we favor two conclusions: First, PIM1 mutations in DLBCL result overwhelmingly from aberrant AID activity and are driven primarily by this biology than by a process in which mutations to PIM1 are a primary or required tumorigenic process. This evidence concerns the gene AICDA and diffuse large B-cell lymphoma.